A Study on the Efficacy of Androgen Deprivation Therapy Combined With Anti-PD-1 Therapy in Advanced Lung Cancer

Inclusion Criteria13

• Male patients aged ≥60 years.
• ECOG performance status score of 0 ~1.
• Expected survival time of more than 3 months.
• Histologically or cytologically diagnosed advanced lung cancer according to the TNM staging system established by AJCC.
• Patients who have not previously received any anti-PD-1 treatment.
• Patients with adequate bone marrow function, no significant hepatic, renal, or coagulation dysfunction as per laboratory test criteria.
• At least one tumor lesion meeting the following criteria:
• No prior local treatments such as radiotherapy
• Not biopsied during the screening period (if biopsy needed, baseline tumor assessment at least 14 days after the screening biopsy).
• Measurable at baseline (longest diameter of the lesion ≥10 mm; For a lymph node, short diameter ≥15 mm).
• If only one measurable lesion, no prior local treatments such as radiotherapy.
• Ability to understand and voluntarily sign a written informed consent form.
• Willingness to follow the study protocol and follow-up examinations.